CytoDyn CYDY
OTC CYDY
$0.20 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

CytoDyn (CYDY) Gains from Sales and Divestitures (2011 - 2012)

Updated

CytoDyn (CYDY) recorded Gains from Sales and Divestitures of -$583.00 in FY2015 (year ended May 31, 2015).

Analysis

CytoDyn (CYDY) Gains from Sales and Divestitures (2011 - 2012) Analysis & Trends

  • The FY2015 figure is the lowest annual Gains from Sales and Divestitures since FY2012.
  • Per Business Quant data, CYDY's Gains from Sales and Divestitures was -$2,560 in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 CytoDyn 274.70 Mn 274.70 Mn -
Historic Data

Historic Data

Download Data
DateValue
May 31, 2012 293.00
Feb 29, 2012 293.00
Nov 30, 2011 290.00
Aug 31, 2011 -3,436.00
API Access

CytoDyn Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CYDY&period=max&api_key=YOUR_API_KEY